Vitamin D Supplementation in People at Risk of Type 2 Diabetes V1.3

• Research type

  Research Study

• Full title

  A randomized, double blind, placebo controlled, phase II, multi-centre pilot study to investigate the effects of vitamin D2 or D3 supplementation on metabolic parameters in people at risk of type 2 diabetes.

• IRAS ID

  12085

• Contact name

  Graham Hitman

• Contact email

  g.a.hitman@qmul.ac.uk

• Sponsor organisation

  Queen Mary University of London

• Eudract number

  2009-011264-11

• ISRCTN Number

  Applied for

• Research summary

  Diabetes (inadequate regulation of sugar in body) is a growing global problem. Diabetes in turn increases the risk of developing heart attacks, strokes, kidney failure, blindness and loss of limbs. Several studies have shown that modifying lifestyle and certain drugs can prevent the onset of diabetes. However, it is also clear that additional strategies need to be identified.
  Vitamin D deficiency is increasingly recognised as being very common. Whilst it is commonly acknowledged to be important for bone health, it is also involved in the way the body handles sugar and may even protect from heart attacks and strokes. We aim to see whether giving vitamin D (of which there are two main forms available in the market currently, D2 and D3) to people identified as being at a high risk of developing diabetes, would prevent or delay the onset of diabetes. We also aim to check the acceptability and safety of supplementation and see how it might affect factors also associated with heart disease, such as blood pressure.

• REC name

  London - Fulham Research Ethics Committee

• REC reference

  09/H0711/85

• Date of REC Opinion

  22 Dec 2009

• REC opinion

  Further Information Favourable Opinion